---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-008887"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2022-02-23T23:59:59+00:00"
generated_at: "2026-06-27T05:34:06.852266+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# InMed board director Catherine Sazdanoff resigns; Janet Grove appointed as replacement

## Summary
- Catherine Sazdanoff resigned from Board effective Feb 11, 2022 due to personal reasons.
- Janet Grove appointed as director effective Feb 11, 2022 to fill vacancy; term expires at 2022 AGM.
- Grove to serve on Compensation and Nominating & Governance Committees.
- Grove receives $35K annual retainer, up to $15K for committee service, plus stock options for 14,000 shares.

## SEC filing metadata
- accession: 0001213900-22-008887
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2022-02-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/0001213900-22-008887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/ea156089-8k_inmedpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-008887
- JSON: https://secwatch.observer/filing/0001213900-22-008887.json
- Plain text: https://secwatch.observer/filing/0001213900-22-008887.txt

## Key facts
- Executive change
  Catherine Sazdanoff resigned as Director at InMed Pharmaceuticals Inc..
  - Action: resigned
  - Role: Director
  source text: On February 11, 2022, Catherine Sazdanoff resigned from the Board of Directors (the “Board”) (including from the Compensation Committee, the Nominating & Governance Committee and the Audit Committee) of InMed Pharmaceuticals Inc. (the “Company”), effective as of February 11,2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/0001213900-22-008887-index.htm
- Executive change
  Janet Grove was appointed as Director at InMed Pharmaceuticals Inc..
  - Action: appointed
  - Role: Director
  source text: On February 11, 2022, the Board appointed Janet Grove as a director of the Board to fill the vacancy created by Ms. Sazdanoff’s resignation, effective as of February 11, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/0001213900-22-008887-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.